the evidence record / cited
PT-141 research: what the trials measured, and how large the effect really is
From rat solicitation studies to two Phase 3 RCTs and a 52-week extension — the published record on bremelanotide, with the effect-size debate kept in plain view.
The short version
PT-141 research runs from rats to a large human program. In rodents and primates it produced erections and switched on sexual-desire circuits in the brain [1][2]. In premenopausal women with HSDD, two big Phase 3 trials (RECONNECT, 1,267 women) found it improved desire and lowered desire-related distress versus placebo, and a year-long follow-up showed the benefit held [3][4]. A brain-imaging study confirmed it changes how the brain handles sexual cues [5]. The honest caveat: independent analysts argue the size of the benefit is small [12]. This page lays out both the findings and that debate, every quantitative claim cited.
How the evidence stacks: from rat models to approval
The bremelanotide record built up in stages, each resting on the one before. The earliest pharmacology established a central melanocortin mechanism: PT-141, an alpha-MSH analogue and MC3R/MC4R agonist, produced dose-dependent erections in rats and nonhuman primates, activated hypothalamic neurons, and produced rapid erectile activity in men with erectile dysfunction in early studies [1]. A 2004 PNAS study then showed the system specifically governs desire — in female rats, PT-141 selectively increased appetitive, solicitational sexual behavior without affecting reflexive lordosis, pacing, or general motor activity, the first pharmacological agent reported to act on appetitive female sexual behavior [2]. Phase 2 dose-finding in women narrowed the dose to three candidates (0.75, 1.25, and 1.75 mg), and the two RECONNECT Phase 3 trials then tested 1.75 mg against placebo [3]. Approval followed in 2019, and a 52-week open-label extension characterized long-term use [4][6].
PT-141 in the research literature: what the studies report
The published literature on PT-141 (bremelanotide) is unusually deep for a compound also sold as a research chemical: two pivotal Phase 3 RCTs, a 52-week extension, Phase 2 dose-ranging, a mechanistic fMRI study, and several expert reviews and a first-approval summary [3][4][5][6][8][9]. The headline efficacy result comes from RECONNECT: across both identical trials in 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg as-needed met both coprimary endpoints over 24 weeks — improved FSFI-desire (+0.35, P<.001) and reduced FSDS-DAO item-13 distress (−0.33, P<.001) versus placebo [3]. Expert appraisals have since weighed its benefit-risk and place in therapy for premenopausal women [9], while an approval-era clinical review summarized the pharmacology, efficacy, and dosing for practitioners [8].
What benefits did the trials measure?
The trials measured two things: sexual desire (FSFI-desire domain) and the distress that low desire causes (FSDS-DAO item 13) [3]. Both improved significantly versus placebo, and the gains were sustained over 52 weeks of open-label use [4]. These are the measured endpoints, reported as findings — not a promise of benefit for any individual, and, as the next section notes, the size of the effect is contested.
How large is the effect? The honest debate
The RECONNECT results were statistically significant. Whether they are clinically meaningful is genuinely debated, and this site keeps that debate in plain view. The integrated treatment effects — FSFI-desire +0.35 and FSDS-DAO item-13 −0.33 — are real but modest [3]. A 2021 re-analysis of the Phase 3 data argued the observed effects on desire and distress were small and questioned their clinical meaningfulness and the choice of outcome measures [12]. Reading that critique alongside the trial reports is the fair way to understand the evidence: the drug does more than placebo on validated scales, by a margin reasonable people describe as small. Expert reviews appraising its place in therapy have engaged this same question of benefit magnitude [9].
Mechanism in humans: the imaging evidence
Direct human mechanistic data comes from a 2022 Journal of Clinical Investigation study. In a randomized, double-blind, placebo-controlled crossover fMRI experiment in 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli — enhancing amygdala-insula functional connectivity and cerebellar/supplementary-motor activity [5]. That is mechanistic confirmation, in humans, that a melanocortin agonist modulates central sexual brain processing rather than peripheral physiology. A 2025 Neuropharmacology study in female Syrian hamsters added nuance from the other direction: MC3R/MC4R mRNA concentrated in ventral-tegmental-area dopamine neurons, but bremelanotide did not change melanocortin-receptor expression in the mesolimbic dopamine system and did not enhance sexual reward in a place-preference test — a careful negative finding suggesting it may not act on the classic VTA-NAc reward circuit [13]. The newest clinical-management reviews continue to place bremelanotide within current HSDD pharmacotherapy [14][15].
What does PT-141 do for women?
In premenopausal women with HSDD, the RECONNECT Phase 3 trials found bremelanotide produced statistically significant but modest improvements in sexual desire and reduced desire-related distress versus placebo over 24 weeks [3].